Published in J Antimicrob Chemother on December 09, 2012
In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies. Antimicrob Agents Chemother (2015) 0.83
Invasive candidiasis in non neutropenic critically ill - need for region-specific management guidelines. Indian J Crit Care Med (2015) 0.75
Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis. PLoS One (2015) 0.75
Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum. Mycopathologia (2017) 0.75
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med (2014) 2.95
Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis (2014) 1.73
Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther (2009) 1.68
Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis (2003) 1.54
Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother (2004) 1.50
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol (2006) 1.43
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis (2011) 1.42
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. Diagn Microbiol Infect Dis (2003) 1.25
Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother (2013) 1.19
Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother (2011) 1.17
Food and probiotic strains from the Saccharomyces cerevisiae species as a possible origin of human systemic infections. Int J Food Microbiol (2006) 1.14
Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study. Antimicrob Agents Chemother (2005) 1.13
Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother (2003) 1.12
Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol (2012) 1.12
Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother (2003) 1.11
Risk Factors for Anastomotic Leak After Colon Resection for Cancer: Multivariate Analysis and Nomogram From a Multicentric, Prospective, National Study With 3193 Patients. Ann Surg (2015) 1.11
Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis (2004) 1.08
In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother (2010) 1.08
Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemother (2006) 1.08
Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev Anti Infect Ther (2009) 1.04
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents (2008) 1.03
Disseminated histoplasmosis with hemophagocytic syndrome in a patient with AIDS: description of one case and review of the Spanish literature. Rev Iberoam Micol (2007) 1.01
Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry. J Clin Microbiol (2005) 1.01
Antifungal activity against Candida biofilms. Int J Artif Organs (2012) 1.01
Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol (2003) 1.01
An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis (2007) 0.99
Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother (2005) 0.98
Assessment of two new molecular methods for identification of Candida parapsilosis sensu lato species. J Clin Microbiol (2011) 0.97
Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. J Antimicrob Chemother (2012) 0.96
Altered antioxidant-oxidant status in the aqueous humor and peripheral blood of patients with retinitis pigmentosa. PLoS One (2013) 0.96
Rapid method for testing the susceptibility of Aspergillus fumigatus to amphotericin B, itraconazole, voriconazole and posaconazole by assessment of oxygen consumption. J Antimicrob Chemother (2008) 0.92
Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol (2013) 0.91
Differentiation of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis by specific PCR amplification of the RPS0 intron. Int J Med Microbiol (2011) 0.90
In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. Antimicrob Agents Chemother (2009) 0.90
Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts. J Antimicrob Chemother (2007) 0.89
A simple transcriptomic signature able to predict drug-induced hepatic steatosis. Arch Toxicol (2014) 0.89
Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag (2006) 0.86
Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy. Rev Iberoam Micol (2006) 0.85
Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates. Diagn Microbiol Infect Dis (2011) 0.84
Status of medical mycology education. Med Mycol (2003) 0.83
Comparison of posaconazole and voriconazole in vitro killing against Candida krusei. Diagn Microbiol Infect Dis (2008) 0.83
Comparative evaluation of ATB Fungus 2 and Sensititre YeastOne panels for testing in vitro Candida antifungal susceptibility. Rev Iberoam Micol (2008) 0.82
Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp. J Clin Microbiol (2004) 0.82
[Value of Aspergillus galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patients]. Rev Iberoam Micol (2003) 0.82
Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J Am Acad Dermatol (2011) 0.82
Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther Clin Risk Manag (2008) 0.79
The aspHS gene as a new target for detecting Aspergillus fumigatus during infections by quantitative real-time PCR. Med Mycol (2013) 0.79
[Antifungal treatment options in the critically ill patient]. Rev Iberoam Micol (2012) 0.79
Effect of statin use on outcomes of adults with candidemia. PLoS One (2013) 0.79
[Current treatment of candidemia. Role of anidulafungin]. Enferm Infecc Microbiol Clin (2008) 0.78
Comparison of assessment of oxygen consumption, Etest, and CLSI M38-A2 broth microdilution methods for evaluation of the susceptibility of Aspergillus fumigatus to posaconazole. Antimicrob Agents Chemother (2009) 0.78
Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina. J Neuroinflammation (2014) 0.78
[Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNFalpha) therapy]. Rev Iberoam Micol (2009) 0.78
[In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms]. Rev Iberoam Micol (2007) 0.78
Comparison of E-Test, disk diffusion and a modified CLSI broth microdilution (M 38-A) method for in vitro testing of itraconazole, fluconazole and voriconazole against dermatophytes. Med Mycol (2008) 0.78
[In vitro antifungal activity of micafungin]. Rev Iberoam Micol (2009) 0.78
[Age group, geographical incidence and patterns of antifungal susceptibility of Candida species causing candidemia in the Spanish paediatric population]. Enferm Infecc Microbiol Clin (2013) 0.78
Kinetic patterns of Candida albicans germ tube antibody in critically ill patients: influence on mortality. Clin Vaccine Immunol (2009) 0.77
A score model for the continuous grading of early allograft dysfunction severity. Liver Transpl (2014) 0.77
Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp. Diagn Microbiol Infect Dis (2012) 0.76
[In vitro activity of voriconazole and three other antifungal agents against dermatophytes]. Enferm Infecc Microbiol Clin (2003) 0.75
[Microbiological procedures for diagnosing mycoses and for antifungal susceptibility testing]. Enferm Infecc Microbiol Clin (2007) 0.75
Relaxant Effects of the Selective Estrogen Receptor Modulator, Bazedoxifene, and Estrogen Receptor Agonists in Isolated Rabbit Basilar Artery. J Cardiovasc Pharmacol (2016) 0.75
[Nine-year-old child with chronic abdominal pain]. Enferm Infecc Microbiol Clin (2003) 0.75
[Is the use of antifungal management advisable in critical patients with positive isolation of Candida spp. from intraabdominal clinical samples?]. Rev Iberoam Micol (2008) 0.75
[Pocket guide to invasive mycoses in onco-hematologic patients]. Rev Iberoam Micol (2009) 0.75
[Invasive mycoses in the critically ill patient]. Rev Iberoam Micol (2012) 0.75
[Rapid identification of Candida dubliniensis using the Bichro-Dubli test]. Enferm Infecc Microbiol Clin (2007) 0.75
[Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) guidelines for the diagnosis of invasive fungal infections. 2010 update]. Enferm Infecc Microbiol Clin (2010) 0.75
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis (2006) 0.75
[Epidemiological profile and sensitivity pattern of isolates causing invasive fungal infection vs. colonizing isolates in non-neutropenic critically ill patients]. Rev Iberoam Micol (2012) 0.75
[In vitro antifungal activity of voriconazole: New data after the first years of clinical experience]. Rev Iberoam Micol (2007) 0.75